Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
4 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 15 · 2009–2026
Showing the 50 most relevant studies, sorted by most relevant.
Kola-Mustapha AT, Raji MA, Zarroug SHO, et al.
2025
- Acne Vulgaris
- Inflammation
- Gentamicins
Ludmila Motelică, D. Ficai, O. Oprea, et al.
Pharmaceutics, 2021
Ruchi Sharma, Rekha Rao, Sunil Kumar, et al.
Current Drug Discovery Technologies, 2019
Ashaq B, Rasool K, Habib S, et al.
2024
Lemongrass essential oil (LEO), extracted from high-oil lemongrass, gains prominence as a versatile natural product due to growing demand for safe health solutions. LEO comprises beneficial compounds like citral, isoneral, geraniol, and citronellal, offering diverse pharmacological benefits such as antioxidant, antifungal, antibacterial, antiviral, and anticancer effects. LEO finds applications in food preservation, cosmetics, and pharmaceuticals, enhancing profitability across these sectors. The review focuses on the extraction of LEO, emphasizing the need for cost-effective methods. Ultrasound and supercritical fluid extraction are effective in reducing extraction time, increasing yields, and enhancing oil quality. LEO shows promise as a valuable natural resource across industries, with applications in packaging, coating, and film development. LEO's ability to extend the shelf life of food items and impart natural flavors positions it as a valuable asset. Overall, the review emphasizes LEO's therapeutic, antimicrobial, and antioxidant properties, strengthening its potential in the food, pharmaceutical, and cosmetic sectors.
Abstract licence: CC BY
N. R. Putra, A. H. Abdul Aziz, Dwila Nur Rizkiyah, et al.
Pertanika Journal of Science and Technology, 2024
Bava R, Bulotta RM, Castagna F, et al.
2026
Background: The control of fleas and ticks in companion animals is a persistent challenge with animal welfare and public health implications. The increasing resistance to antiparasitic treatments, coupled with concerns over the environmental impact and non-target effects of synthetic acaricides, has driven interest in sustainable alternatives. Essential oils (EOs) have emerged as potential candidates due to their complex chemistry and modes of action. Methods: This review critically analyzes the scientific literature on essential oils for ectoparasite control in companion animals. Specifically, it examines their chemical composition, multi-target mechanisms of action, laboratory and field efficacy, role in resistance mitigation, and integration into IPM strategies. Results: Several EOs, particularly those rich in phenolic compounds (thymol, carvacrol, eugenol, and cinnamaldehyde), demonstrate promising in vitro insecticidal and acaricidal activity. Their multi-target mechanisms, affecting neuronal, respiratory, and cuticular functions, not only provide efficacy but also represent a significant barrier to rapid resistance development. However, their translation to reliable field performance is hampered by high volatility, formulation instability, and innate variability. Conclusions: EOs represent a valuable source of bioactive compounds for reducing reliance on conventional acaricides and can play a key role within IPM strategies. To realize their full potential in mitigating resistance, focused advancements are needed in standardized testing, formulation science to enhance stability and residual activity, and rigorous field studies to confirm safety and efficacy.
Abstract licence: CC BY
Moreno-Bohorquez E, Arias-Tapia MJ, Jaramillo AF
2026
Thermoplastic starch (TPS) blended with biodegradable polyesters such as polyhydroxybutyrate (PHB), polylactic acid (PLA), polybutylene succinate (PBS), and polycaprolactone (PCL) represents a promising route toward sustainable alternatives to petroleum-based plastics. TPS offers advantages related to abundance, low cost, and biodegradability, while polyesters provide improved mechanical strength, thermal stability, and barrier performance. However, the intrinsic incompatibility between hydrophilic TPS and hydrophobic polyesters typically leads to immiscible systems with poor interfacial adhesion and limited performance. This review critically examines recent advances in the development of TPS/polyester blends, with emphasis on compatibilization strategies based on chemical modification, natural and synthetic compatibilizers, bio-based additives, and reinforcing agents. Particular attention is given to the role of organic acids, essential oils, phenolic compounds, nanofillers, and natural reinforcements in controlling morphology, crystallinity, interfacial interactions, and thermal-mechanical behavior. In addition, the contribution of bioactive additives to antimicrobial and antioxidant functionality is discussed as an emerging multifunctional feature of some TPS/polyester systems. Finally, current limitations related to long-term stability, scalability, and life cycle assessment are highlighted, identifying key challenges and future research directions for the development of advanced biodegradable materials with tailored properties.
Abstract licence: CC BY
Akacha BB, Kačániová M, Kukula-Koch W, et al.
2026
- Oils, Volatile
- Antioxidants
- Anti-Infective Agents
The growing interest in natural alternatives to synthetic additives has driven research into essential oils (EOs) for antimicrobial and antioxidant applications. Statistical mixture design approaches provide effective tools to optimize multi-component EO blends for enhanced bioactivity. This review presents an overview of recent advances in applying mixture design methodologies, such as simplex lattice and simplex centroid designs, to develop EO combinations with improved antimicrobial and antioxidant activity. We summarize key findings on blend synergies, discuss mechanisms underlying enhanced efficacy, and highlight case studies where optimized mixtures outperform the action of individual EOs. Current patents and practical applications of optimized EO blends are reviewed, and future research directions are proposed, including multi-component formulations, encapsulation approaches, and machine learning-driven optimization. By synthesizing these insights, this review highlights mixture design as a sustainable and innovative approach to developing eco-friendly, effective EO-based antimicrobial and antioxidant formulations.
Abstract licence: CC BY
Lezeck H, Martí M, Saxena S, et al.
2026
- Oils, Volatile
- Anti-Bacterial Agents
- Textiles
Essential oils (EOs) are well-known in traditional medicine, pharmacy, the food industry, and cosmetics because they are readily available and have proven efficacy across a wide range of applications. They are natural, bio-based, and biodegradable, and when applied accurately, they exhibit effective action against microorganisms, viruses, and fungi. However, most organic EOs are volatile and have hydrophobic surface chemistry, making them unsuitable for direct bio-applications in textiles. Textiles offer a useful platform for applying essential oils to impart functions such as antimicrobial or deodorizing effects. While traditional textiles focused mainly on comfort and protection, the rise of functional textiles has created new opportunities to integrate natural compounds such as essential oils. Recently, a growing body of research has focused on integrating essential oils into textile materials, driven by the increasing demand for sustainable fabrics with added biofunctionality. This review highlights the latest advances in applying essential oils to textile substrates and examines the techniques used and the improvements achieved, including washing cycles, antibacterial efficiency ranges, and durability. We survey recent literature, including research papers, articles, and books, to identify the most common methods and clarify their underlying mechanisms.
Abstract licence: CC BY
Saavedra DI, Carter DT, Dawson JT, et al.
2026
- Curcuma
- Rhizome
- Oils, Volatile
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Citronella oil
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72